Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz’s Saynor Sees Tipping Point For Biosimilars

Several Factors Are Combining To Push Industry Forward, Says Sandoz CEO

Executive Summary

A combination of factors – including recent moves in the UK to broaden access to biosimilars for rheumatoid arthritis patients, as well as the new MHRA pathway for biosimilars and a growing call for global regulatory alignment – are contributing to a “biosimilar Zeitgeist” that could see long-in-the-making change coming for the industry, according to Sandoz CEO Richard Saynor.

You may also be interested in...



Health Canada Ponders UK Model On Easing Biosimilar Study Requirements

Discussions are ongoing at Health Canada on the feasibility of adopting the UK model of easing clinical study requirements for biosimilars, said director general Celia Lourenco at a recent event. Meanwhile, the US FDA’s stance is unchanged for now.

Health Canada Ponders UK Model On Easing Biosimilar Study Requirements

Discussions are ongoing at Health Canada on the feasibility of adopting the UK model of easing clinical study requirements for biosimilars, said director general Celia Lourenco at a recent event. Meanwhile, the US FDA’s stance is unchanged for now.

Sandoz’s Bourdage Makes Case For Tailored Biosimilar Pathways

A strong case exists for a more tailored approach to biosimilars development that could increase regulatory efficiency and broaden access, Sandoz’s head of biopharmaceuticals, Pierre Bourdage, tells Generics Bulletin in an exclusive interview.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel